Member States were next asked a series of questions related to
safety and herbal medicines. The first question asked countries
to describe those regulatory requirements used for the safety
assessment of herbal medicines. The following options were
given: same requirements as for conventional pharmaceuticals,
special requirements or no requirements. If Member States chose
the option “special requirements”, they were further asked to
choose all that applied from the following options: traditional
use without demonstrated harmful effects, reference to
documented scientific research on similar products, and other
requirements. If other requirements were selected, the
respondents were asked to describe the requirement. A total of
130 Member States responded to this question: however, as
respondents were asked to choose all that applied, there are
more responses than respondents for this question (Figure 30).
Eighty two countries indicated that special regulatory
requirements exist for herbal medicine. Of the remai